Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.984
−$0.0013 · -0.13%
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Previous close
$0.984
−$0.0013 · -0.13%
After-hours
$1.0054
+$0.0214 · +2.17%
Oct 7, 7:06 PM ET
Regular session · ET · Market data may be delayed.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $0.984
52-week range
Current $0.984
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
54
Mixed
Risk
67
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $0.984
52-week range
Current $0.984
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 11, 2024 | 1:30 | — | — |
Stock split | Apr 9, 2024 | 1:20 | — | — |
Stock split | Jun 29, 2023 | 1:40 | — | — |
Stock split | Mar 27, 2023 | 1:35 | — | — |
Effective Sep 11, 2024
1:30
Effective Apr 9, 2024
1:20
Effective Jun 29, 2023
1:40
Effective Mar 27, 2023
1:35
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
